https://www.selleckchem.com/products/azd9291.html
The probability that adrenaline is cost-effective was less than 1% across a range of cost-effectiveness thresholds. Combined direct economic effects over the lifetimes of survivors and indirect economic effects in organ recipients produced an ICER of £16,086 (€18,499) per QALY gained for adrenaline with the probability that adrenaline is cost-effective increasing to 90% at a £30,000 (€34,50 per QALY cost-effectiveness threshold. Adrenaline was not cost-effective when only directly related costs and consequences are considered. However
Curtir
Comentario
Compartilhar
